Extensive R&D capabilities and world-class expertise is available at WuXi XDC to generate, engineer, evaluate and optimize antibody drug conjugate (ADC)/bioconjugate lead candidates including trouble-shooting and overcoming the challenges associated with complex bioconjugated moieties. Wide-ranging R&D of the bioconjugation key intermediates including mAb/protein
, payload and linkers is also available and is the cornerstone of the WuXi XDC technology platform.
- Many types of conjugations utilizing multiple linkers and payloads is available as demonstrated in the following table:
Antibody and payload conjugation development utilizing multiple technologies including WuXi XDC proprietary technologies (e.g., WuXiDAR4 Drug Antibody Ratio Technology Platform ) is available from our large team of highly trained scientists.